Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 31, 2007

Medarex and Mitsubishi Join Forces to Target Autoimmune Diseases

  • Medarex is partnering with Mitsubishi Pharma to generate and evaluate fully human mAbs against a Mitsubishi target for the treatment of autoimmune diseases.

    The companies will use Medarex' UltiMAb Human Antibody Development System® to generate antibodies. The companies will share research responsibilities for any antibodies found through the collaboration.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »